Core Viewpoint - Kairos Pharma, Ltd. is hosting a KOL event to discuss interim efficacy results from a Phase 2 trial of its lead candidate ENV105 for advanced prostate cancer treatment [1] Company Summary - Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics [1] - The KOL event is scheduled for Thursday, September 18th at 5 p.m. ET / 2 p.m. PT [1] - Registration is required to participate in the webcast [1] Industry Context - The event will provide diverse perspectives on the efficacy results, indicating a focus on collaboration and expert insights within the oncology sector [1]